Treatment of inflamed pterygia or residual pterygial bed.

Abstract

AIMS:

To describe the use of subconjunctival bevacizumab or ranibizumab, an approved antivascular endothelial growth factor for wet macular degeneration, in halting the inflammation of a pterygium or a partially excised pterygium.

METHODS:

Case reports.

RESULTS:

Prompt regression of conjunctival microvessels in the pterygial bed was documented 1 week after a single subconjunctival injection of ranibizumab (one case) or bevacizumab (two cases). No side-effects were noted over 13 months of follow-up in the first case, 6 months in the second case and 1 month in the third case.

CONCLUSION:

Selective blockade of vascular endothelial growth factor was effective in causing regression of conjunctival microvessels in three eyes with inflamed pterygium or residual pterygia.

• Authors: A M Mansour
• Journal: The British journal of ophthalmology (Br J Ophthalmol) Vol. 93 Issue 7 Pg. 864-5 (Jul 2009) ISSN: 1468-2079 [Electronic] England
• PMID: 19553512 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Ranibizumab

Topics

• Aged
• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Conjunctiva (blood supply)
• Corneal Neovascularization (drug therapy)
• Female
• Humans
• Macular Degeneration (drug therapy)
• Male
• Microvessels (drug effects)
• Middle Aged
• Phacoemulsification
• Pterygium (drug therapy)
• Ranibizumab
• Vitrectomy